Role of P-glycoprotein and permeability upon the brain distribution and pharmacodynamics of etamicastat: a comparison with nepicastat

References

• Almeida L, Nunes T, Costa R, et al. (2013). Etamicastat, a novel dopamine beta-hydroxylase inhibitor: tolerability, pharmacokinetics, and pharmacodynamics in patients with hypertension. Clin Ther 35:1983–96
   PubMed Web of Science ®Google Scholar
• Beliaev A, Ferreira H, Learmonth DA, Soares-da-Silva P. (2009). Dopamine β-monooxygenase: mechanism, substrates and inhibitors. Curr Enzyme Inhibit 5:27–43
   Google Scholar
• Beliaev A, Learmonth DA, Soares-da-Silva P. (2006). Synthesis and biological evaluation of novel, peripherally selective chromanyl imidazolethione-based inhibitors of dopamine beta-hydroxylase. J Med Chem 49:1191–7
   PubMed Web of Science ®Google Scholar
• Bihorel S, Camenisch G, Lemaire M, Scherrmann JM. (2007). Influence of breast cancer resistance protein (Abcg2) and p-glycoprotein (Abcb1a) on the transport of imatinib mesylate (Gleevec) across the mouse blood-brain barrier. J Neurochem 102:1749–57
   PubMed Web of Science ®Google Scholar
• Braggio S, Montanari D, Rossi T, Ratti E. (2010). Drug efficiency: a new concept to guide lead optimization programs towards the selection of better clinical candidates. Expert Opin Drug Discov 5:609–18
   PubMed Web of Science ®Google Scholar
• DeQuattro V, Sjoerdsma A. (1968). Catecholamine turnover in normotensive and hypertensive man: effects of antiadrenergic drugs. J Clin Invest 47:2359–73
   PubMed Web of Science ®Google Scholar
• Eisenhofer G, Kopin IJ, Goldstein DS. (2004). Catecholamine metabolism: a contemporary view with implications for physiology and medicine. Pharmacol Rev 56:331–49
   PubMed Web of Science ®Google Scholar
• Esler M, Kaye D. (2000). Sympathetic nervous system activation in essential hypertension, cardiac failure and psychosomatic heart disease. J Cardiovasc Pharmacol 35:S1–7
   PubMed Web of Science ®Google Scholar
• Gomes P, Soares-da-Silva P, (2008). Dopamine. In: Baden M, ed. Cardiovascular hormone systems: from molecular mechanisms to novel therapeutics. Weinheim: Wiley-VCH, 251–93
   Google Scholar
• Grassi G. (2010). Sympathetic neural activity in hypertension and related diseases. Am J Hypertens 23:1052–60
   PubMed Web of Science ®Google Scholar
• Grassi G, Bolla G, Quarti-Trevano F, et al. (2008). Sympathetic activation in congestive heart failure: reproducibility of neuroadrenergic markers. Eur J Heart Fail 10:1186–91
   PubMed Web of Science ®Google Scholar
• Grassi G, Seravalle G, Quarti-Trevano F. (2010). The ‘neuroadrenergic hypothesis' in hypertension: current evidence. Exp Physiol 95:581–6
   PubMed Web of Science ®Google Scholar
• Hegde SS, Friday KF. (1998). Dopamine-beta-hydroxylase inhibition: a novel sympatho-modulatory approach for the treatment of congestive heart failure. Curr Pharm Des 4:469–79
   PubMed Web of Science ®Google Scholar
• Hubensack M, Muller C, Hocherl P, et al. (2008). Effect of the ABCB1 modulators elacridar and tariquidar on the distribution of paclitaxel in nude mice. J Cancer Res Clin Oncol 134:597–607
   PubMed Web of Science ®Google Scholar
• Igreja B, Pires NM, Bonifacio MJ, et al. (2015). Blood pressure-decreasing effect of etamicastat alone and in combination with antihypertensive drugs in the spontaneously hypertensive rat. Hypertens Res 38:30–8
   PubMed Web of Science ®Google Scholar
• Igreja B, Pires NM, Wright L, Soares-da-Silva P. (2008). Effect of combined administration of BIA 5-453 and captopril on blood pressure and heart rate. Hypertension 52:E62 (abstract)
   Web of Science ®Google Scholar
• Igreja B, Pires NM, Wright LC, Soares-da-Silva P. (2011). Antihypertensive effects of a selective peripheral dopamine beta-hydroxylase inhibitor alone or in combination with other antihypertensive drugs. Hypertension 58:E161–2
   PubMed Web of Science ®Google Scholar
• Ishii Y, Fujii Y, Mimura C, Umezawa H. (1975). Pharmacological action of FD-008, a new dopamine beta-hydroxylase inhibitor. I. Effects on blood pressure in rats and dogs. Arzneimittelforschung 25:55–9
   PubMed Web of Science ®Google Scholar
• Jose PA, Eisner GM, Felder RA. (2002). Role of dopamine receptors in the kidney in the regulation of blood pressure. Curr Opin Nephrol Hypertens 11:87–92
   PubMed Web of Science ®Google Scholar
• Jose PA, Soares-da-Silva P, Eisner GM, Felder RA. (2010). Dopamine and G protein-coupled receptor kinase 4 in the kidney: role in blood pressure regulation. Biochim Biophys Acta 1802:1259–67
   PubMed Web of Science ®Google Scholar
• Kalvass JC, Maurer TS. (2002). Influence of nonspecific brain and plasma binding on CNS exposure: implications for rational drug discovery. Biopharm Drug Dispos 23:327–38
   PubMed Web of Science ®Google Scholar
• Kamiie J, Ohtsuki S, Iwase R, et al. (2008). Quantitative atlas of membrane transporter proteins: development and application of a highly sensitive simultaneous LC/MS/MS method combined with novel in-silico peptide selection criteria. Pharm Res 25:1469–83
   PubMed Web of Science ®Google Scholar
• Kruse LI, Kaiser C, DeWolf WE Jr, et al. (1986). Substituted 1-benzylimidazole-2-thiols as potent and orally active inhibitors of dopamine beta-hydroxylase. J Med Chem 29:887–9
   PubMed Web of Science ®Google Scholar
• Kruse LI, Kaiser C, DeWolf WE Jr, et al. (1987). Multisubstrate inhibitors of dopamine beta-hydroxylase. 2. Structure-activity relationships at the phenethylamine binding site. J Med Chem 30:486–94
   PubMed Web of Science ®Google Scholar
• Lee CS, Tkacs NC. (2008). Current concepts of neurohormonal activation in heart failure: mediators and mechanisms. AACN Adv Crit Care 19:364–85
   PubMedGoogle Scholar
• Loureiro AI, Joao Bonifacio M, Fernandes-Lopes C, et al. (2014). Etamicastat, a new dopamine-β-hydroxylase inhibitor, pharmacodynamics and metabolism in rat. Eur J Pharmacol 740:285–94
   PubMed Web of Science ®Google Scholar
• Malpas SC. (2010). Sympathetic nervous system overactivity and its role in the development of cardiovascular disease. Physiol Rev 90:513–57
   PubMed Web of Science ®Google Scholar
• Mancia G, Grassi G, Giannattasio C, Seravalle G. (1999). Sympathetic activation in the pathogenesis of hypertension and progression of organ damage. Hypertension 34:724–8
   PubMed Web of Science ®Google Scholar
• Montesinos RN, Moulari B, Gromand J, et al. (2014). Coadministration of P-glycoprotein modulators on loperamide pharmacokinetics and brain distribution. Drug Metab Dispos 42:700–6
   PubMed Web of Science ®Google Scholar
• Ohlstein EH, Kruse LI, Ezekiel M, et al. (1987). Cardiovascular effects of a new potent dopamine beta-hydroxylase inhibitor in spontaneously hypertensive rats. J Pharmacol Exp Ther 241:554–9
   PubMed Web of Science ®Google Scholar
• Pacifici GM, Viani A. (1992). Methods of determining plasma and tissue binding of drugs. Pharmacokinetic consequences. Clin Pharmacokinet 23:449–68
   PubMed Web of Science ®Google Scholar
• Parati G, Esler M. (2012). The human sympathetic nervous system: its relevance in hypertension and heart failure. Eur Heart J 33:1058–66
   PubMed Web of Science ®Google Scholar
• Pfeffer MA, Stevenson LW. (1996). Beta-adrenergic blockers and survival in heart failure. N Engl J Med 334:1396–7
   PubMed Web of Science ®Google Scholar
• Polli JW, Wring SA, Humphreys JE, et al. (2001). Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther 299:620–8
   PubMed Web of Science ®Google Scholar
• Rege BD, Yu LX, Hussain AS, Polli JE. (2001). Effect of common excipients on Caco-2 transport of low-permeability drugs. J Pharm Sci 90:1776–86
   PubMed Web of Science ®Google Scholar
• Sane R, Agarwal S, Elmquist WF. (2012). Brain distribution and bioavailability of elacridar after different routes of administration in the mouse. Drug Metab Dispos 40:1612–19
   PubMed Web of Science ®Google Scholar
• Schwab D, Fischer H, Tabatabaei A, et al. (2003). Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery. J Med Chem 46:1716–25
   PubMed Web of Science ®Google Scholar
• Soares-da-Silva P. (1986). Evidence for a non-precursor dopamine pool in noradrenergic neurones of the dog mesenteric artery. Naunyn Schmiedebergs Arch Pharmacol 333:219–23
   PubMed Web of Science ®Google Scholar
• Soares-da-Silva P. (1987). A comparison between the pattern of dopamine and noradrenaline release from sympathetic neurones of the dog mesenteric artery. Br J Pharmacol 90:91–8
   PubMed Web of Science ®Google Scholar
• Stanley WC, Li B, Bonhaus DW, et al. (1997). Catecholamine modulatory effects of nepicastat (RS-25560-197), a novel, potent and selective inhibitor of dopamine-beta-hydroxylase. Br J Pharmacol 121:1803–9
   PubMed Web of Science ®Google Scholar
• Umeyama Y, Fujioka Y, Okuda T. (2014). Clarification of P-glycoprotein inhibition-related drug-drug interaction risks based on a literature search of the clinical information. Xenobiotica 44:1135–44
   PubMed Web of Science ®Google Scholar